title: How should patients taking the discontinued diabetes drug troglitazone be managed?
authors.affiliation: Department of Endocrinology, Cleveland Clinic, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Reddy
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
chemical_list: D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000410:Alanine Transaminase; D000077288:Troglitazone; D000077205:Pioglitazone